Ê×Ò³ Ò½Ôº¸Å¿ö ÔºÄÚÐÂÎÅ Ò½Áƶ¯Ì¬ ·þÎñµ¼º½ ¾ÍÒ½Ö¸ÄÏ »¤ÀíÌìµØ ÉçÇøÎÀÉú Ò½Ôº¹«¸æ ר¼Ò½éÉÜ ¾«Æ·ÎÄÕÂ
ʡҽѧ»áµÚ¾Å´ÎÁÙ´²ÊäѪѧѧÊõ»áÒé
ÐÄѪ¹Ü½¡¿µÖ¸±ê_Öйú4CÐÄѪ¹ÜÑо¿
µøå´Æð·üµÄÂÈà­ÁÙ´²ÊÔÑ飺´ÓÐÄÔà¶¾
ѪҺ͸Îö²¡È˵ÄС³£Ê¶
ÃÀ¼®½ÌÊÚÓ¦ÑûÀ´ÎÒÔº×÷ѧÊõ½²×ù
±±¾©Ò½ÔºÓë¿ËÀ­ÂêÒÀÊÐÈËÃñÒ½Ôº¿ªÕ¹
³¤É³¾©Ê¯½áʯ²¡Ò½ÔºÃÚÄò½áʯÕïÁÆÐ³ɹûÁÁ
Î÷°²ÊеÚËÄÒ½ÔºÕÙ¿ª¹ãÈÊÇà¹âÑÛѧÊõ»áÒé
еijÉÏñ¼¼ÊõÊÇҽѧÕï¶ÏºÍÑо¿µÄÏȽø¼¼Êõ
È˹¤ÖÇÄÜ¿ÉÒÔ·ÀÖ¹ÐØÍ´Îȶ¨µÄ»¼Õß½øÐв»±Ø
°©Ï¸°û×î¾å7¼þÊ£¬Ö§ÕС°ÈýµÀ·ÀÏß¡±·ÀÖ×
¼±ÕïÍâ¿ÆÒ½Ê¦²Î¼ÓÈ«¹ú´´ÉËѧÊõ»áÒéÇàÄêÒ½
¡¡µ±Ç°Î»ÖÃ>>Ö÷Ò³ > Ò½Áƶ¯Ì¬ > ѧÊõƽ̨ >

¹ÇÉúÎïѧ½øÕ¹£º¹ÇËèÔìѪÇý¶¯¶à·¢ÐÔÓ²»¯Ö¢½øÕ¹

À´Ô´£ºÌì½ò´ó¸Û×ÜÒ½Ôº ×÷ÕߣºÌì½ò´ó¸Û×ÜÒ½Ôº ·¢²¼Ê±¼ä£º2022-07-18 12:05  
Bone marrow hematopoiesis drives multiple sclerosis progression
 
×÷ÕߣºKaibinShi, HandongLi, TingChang ,WenyanHe , YingKong , CaiyunQi , RanLi , HuachenHuang , ZhibaoZhu , PeiZheng , ZheRuan , JieZhou , Fu-DongShi , QiangLiu£¨Department of Neurology, Institute of Neuroimmunology, Tianjin Medical University General Hospital, Tianjin 300052, China£©
 
 
·¢±íÇé¿ö£ºCell.2022 Jun 23;185(13):2234-2247.e17.
 
 doi: 10.1016/j.cell.2022.05.020. Epub 2022 Jun 15.
 
 
 
¿ÆÑ§ÎÊÌâ
 
¶à·¢ÐÔÓ²»¯Ö¢£¨MS£©ÊÇÒ»ÖÖTϸ°û½éµ¼µÄÖÐÊàÉñ¾­ÏµÍ³£¨CNS£©×ÔÉíÃâÒßÐÔ¼²²¡¡£¶ÔÓÚ¶à·¢ÐÔÓ²»¯Ö¢·¢²¡»úÖÆµÄÑо¿¶à¾ÖÏÞÓÚÍâÖÜѪºÍÄÔ¼¹ÒºµÄ×ÔÉí·´Ó¦ÐÔTϸ°û£¬¹ÇËèÔÚÆäÖеÄ×÷ÓÃÈÔȻδ֪¡£
 
 
¿ÆÑ§ÁÁµã
 
1.¶à·¢ÐÔÓ²»¯Ö¢»¼Õß±íÏÖ³öÏÔÖøµÄ¹ÇËèÔöÉú£»
 
2.×ÔÉí·´Ó¦ÐÔ T ϸ°ûÒÔCXCL12-CXCR4 ÖáÒÀÀµÐÔ·½Ê½Ç¨ÒƵ½¹ÇËè¸ôÊÒ£»
 
3.×ÔÉí·´Ó¦ÐÔ T ϸ°ûÔö¼Ó¹ÇËèµÄÉú³É£¬ÕâÖÖÒì³£µÄ¹ÇËèÉú³ÉÉæ¼°ÖÐÊàÉñ¾­ÏµÍ³Ñ×Ö¢ËðÉË¡£
 
 
ÖÐÎÄÕªÒª
 
¶à·¢ÐÔÓ²»¯Ö¢£¨MS£©ÊÇÒ»ÖÖTϸ°û½éµ¼µÄÖÐÊàÉñ¾­ÏµÍ³£¨CNS£©×ÔÉíÃâÒßÐÔ¼²²¡¡£¹ÇËèÔìѪ¸Éϸ°ûºÍ×æÏ¸°û (HSPC) ¿É¿ìËÙ¸ÐÖªÃâÒß¼¤»î£¬µ«ËüÃÇÓë¶à·¢ÐÔÓ²»¯Ö¢ÖÐ×ÔÉí·´Ó¦ÐÔTϸ°ûµÄDZÔÚÏ໥×÷ÓÃÉв»Çå³þ¡£ÔÚÕâÀÑо¿Õß±¨µÀÁËÔÚ¶à·¢ÐÔÓ²»¯Ö¢»¼ÕßÖУ¬¹ÇËèHSPCÆ«Ïò¹ÇËèÆ×ϵ£¬Tϸ°ûÒì³£À©Ôö¡£
ͨ¹ý¶Ô×ÔÉíÃâÒßÐÔÄÔ¼¹ËèÑ×СÊ󣨶෢ÐÔÓ²»¯Ö¢Ð¡ÊóÄ£ÐÍ£©Æ×ϵ׷×Ù֤ʵÁËСÊó¾ßÓÐÒì³£µÄ¹ÇËèÔöÉú£¬°éËæÓÐÏÔÖøÔö¼ÓµÄÖÐÐÔÁ£Ï¸°ûºÍ Ly6Chighµ¥ºËϸ°ûÇÖÈëÖÐÊàÉñ¾­ÏµÍ³¡£Ñо¿Õß·¢ÏÖËèÇÊ·´Ó¦ÐÔTϸ°ûÒÔCXCR4ÒÀÀµÐÔ·½Ê½ÓÅÏÈÇ¨ÒÆµ½¹ÇËè¸ôÊÒ¡£ÕâÖÖÒì³£µÄ¹ÇËèÉú³ÉÉæ¼° CCL5-CCR5 Öá²¢Ôö¼ÓÖÐÊàÉñ¾­ÏµÍ³Ñ×Ö¢ºÍÍÑËèÇÊ¡£¸ÃÑо¿±íÃ÷£¬°ÐÏò¹ÇËèÉú̬λΪÖÎÁƶ෢ÐÔÓ²»¯Ö¢ºÍÆäËû×ÔÉíÃâÒßÐÔ¼²²¡ÌṩÁËÒ»ÌõÓÐЧ;¾¶¡£
 
 
Ó¢ÎÄÕªÒª
 
Multiple sclerosis(MS) is a T cell-mediated autoimmune disease of the central nervous system (CNS). Bone marrow hematopoietic stem and progenitor cells (HSPCs) rapidly sense immune activation, yet their potential interplay with autoreactive T cells in MS is unknown. Here, we report that bone marrow HSPCs are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in MS patients. Lineage tracing in experimental autoimmune encephalomyelitis, a mouse model of MS, reveals remarkable bone marrow myelopoiesis with an augmented output of neutrophils and Ly6Chigh monocytes that invade the CNS. We found that myelin-reactive T cells preferentially migrate into the bone marrow compartment in a CXCR4-dependent manner. This aberrant bone marrow myelopoiesis involves the CCL5-CCR5 axis and augments CNS inflammation and demyelination. Our study suggests that targeting the bone marrow niche presents an avenue to treat MS and other autoimmune disorders.
 
 
 
½á¹û
 
ͼ1£º¹ÇËèϸ°ûÆ×ϵµÄµ¥Ï¸°ûRNA²âÐò½ÒʾMS»¼ÕßµÄÒì³£¹ÇËèÉú³É
 
(A) ¶ÔÀ´×ÔMS»¼Õߺͽ¡¿µ¶ÔÕÕ¸öÌåµÄ¹ÇËèϸ°û½øÐе¥Ï¸°û²âÐòºÍÁ÷ʽϸ°ûÊõ·ÖÎöµÄʵÑéÉè¼Æ¡£
 
(B)HSPCºÍÏÂÓÎϸ°ûÆ×ϵµÄ·½°¸ (×ó)£¬UMAP ͼ£¨ÖУ©ºÍ»ã×ܰٷֱȣ¨ÓÒ£©£¬¹² 108,983 ¸öϸ°û£¬°üÀ¨ HSPC¡¢¹ÇËèϸ°û¡¢ÁܰÍÑùϸ°ûºÍºìϸ°û¡£
 
(C) 10¸ö¾ßÓÐϸ°ûÀàÐÍ×¢Ê͵ļ¯ÈºÁ¦µ¼Ïòͼ¡£
 
(D)MS»¼ÕßÓë¶ÔÕÕ×éϸ°û°Ù·Ö±ÈµÄlog 2±¶Êý¡£
 
(E)¶ÔÕÕ×éºÍMS×éϸ°ûµÄ22,649¸öHSPCµÄÁ¦µ¼Ïòͼ£¨×󣩺ÍСÌáÇÙͼ£¨ÓÒ£©±íÃ÷HSCµÄ¸ÉÐÔ·ÖÊý¡££¨HSC£¬ÔìѪ¸Éϸ°û£»CMP£¬Ëè¹²Í¬×æÏ¸°û£»GMP£¬Á£Ï¸°û-µ¥ºËϸ°û×æÏ¸°û£»MDP£¬µ¥ºËϸ°û-Ê÷ͻ״ϸ°û×æÏ¸°û£»CLP£¬¹²Í¬ÁܰÍ×æÏ¸°û£»NP£¬ÖÐÐÔÁ£Ï¸°ûǰÌ壻MP£¬µ¥ºËϸ°û×æÏ¸°û£©¡£
 
(F)ÈÈͼÏÔʾÓë¶ÔÕÕ×éÏà±ÈMS»¼ÕßÔÚ80%-90%µÄstemnessÆÀ·Ö·¶Î§ÄÚGMPºÍMDPÏà¹Ø»ùÒòÄ£¿éµÄ±í´ï¡£
 
(G)µ÷½Ú×Ó»îÐÔÆÀ·Ö·ÖÎöMS »¼ÕßHSCÖÐÓë¹ÇËè·Ö»¯Ïà¹ØµÄת¼Òò×ӵıí´ï¡£
 
(H)ͨ¹ýt-SNE µÄ¶àά»¹Ô­¾Û¼¯µÄ¹ÇËèϸ°ûÏÔʾTϸ°ûÑÇȺ£¨¶ÔÕÕ£ºÀ´×Ô 7 ÃûÊÜÊÔÕßµÄ 10,266 ¸öϸ°û£»MS£ºÀ´×Ô 7 ÃûÊÜÊÔÕßµÄ 7,246 ¸öϸ°û£©¡£
 
(I)Tϸ°û´ØÎ»ÖÿË¡ϸ°ûµÄŨ¶È¡£
 
(J)¹ÇËèTϸ°ûÑÇȺ½øÐзÖÀà±êÖ¾ÎïµÄ±í´ï¡£
 
(K)TCRαβ¿Ë¡ͼ±íÃ÷MS»¼ÕßµÄϸ°û¿Ë¡ÔöÇ¿¡£
 
(L)MS»¼Õߣ¨% TCRαβ ÐòÁУ©×î´ó¿Ë¡µÄÁ¿»¯Öµ¡£
 
(M)MS»¼ÕßÓë¶ÔÕÕ×éCD4 + Tϸ°û£¨¿Ë¡TCRαβ ≥ 2£©µÄ²îÒì±í´ï·ÖÎö¡£
 
(N)MS»¼ÕßÓë¶ÔÕÕ×é¿Ë¡CD4 + Tϸ°û²îÒì±í´ï»ùÒòµÄͨ··ÖÎö¡£
 
 
ͼ2: ʵÑéÐÔ×ÔÉíÃâÒßÐÔÄÔ¼¹ËèÑ×£¨EAE£©Ð¡Êó¹ÇËèHSCµÄÊýÁ¿ºÍ»îÐÔÔö¼Ó
 
(A) Á÷ʽϸ°û¼ì²â¹ÇËè HSCµÄÃſزßÂÔ¡£
 
(B) ÔÚÖ¸¶¨Ê±¼äµã¼ì²âEAEСÊó¹É¹Ç¹ÇËèÖÐHSCµÄÊýÄ¿¡£
 
(C) BrdU¼ì²âHSCµÄÔöÖ³Çé¿ö¡£
 
(D)×µ¹ÇºÍ¹É¹Ç¹ÇËèµÄ 18F-FDG PET-CT ͼÏñ¡£
 
(E)Á÷ʽϸ°ûÊõÆÀ¹ÀHSCÊýÄ¿¼°ÆäÓëBrdUµÄ½áºÏ¼ì²â½ÓÊܲ»ÍêÈ«¸¥ÊÏ×ô¼Á (IFA)¡¢ÍêÈ«¸¥ÊÏ×ô¼Á (CFA) ºÍ°ÙÈտȶ¾ËØ (PT)¡¢IFA + PT¡¢CFA + PT¡¢OVA323-339 ÃâÒß»ò MOG35-55 ÃâÒßµÄСÊóHSCµÄÔöÖ³Çé¿ö¡£
 
(F)Á÷ʽϸ°ûÊõ·ÖÎö3¸öÔµÄÓ×ÖÉ OT-II СÊó£¨OVA323-339 ÌØÒìÐÔ TCR ת»ùÒò£©ºÍÓ×ÖÉ2D2СÊó£¨MOG35-55 ÌØÒìÐÔ TCR ת»ùÒò£©ÖÐµÄ HSCÊýÁ¿¡£
 
ͼ3£ºEAEСÊó¹ÇËèÖеĹÇËèÉú³ÉÔö¼Ó
 
(A) ¹ÇËè³£¼ûÁܰÍ×æÏ¸°û£¬³£¼û¹ÇËè×æÏ¸°û£¬Á£-µ¥ºË×æÏ¸°ûºÍµ¥ºË-Ê÷Í»×´×æÏ¸°ûµÄÁ÷ʽϸ°ûÊõÃſزßÂÔ¡£
 
(B) ÔÚÖ¸¶¨Ê±¼äµãEAEСÊó¹É¹Ç¹ÇËèÖÐ×æÏ¸°ûµÄƵÂʺÍÊýÄ¿¡£
 
(C) ÃâÒߺóÖ¸¶¨Ê±¼äµã¹ÇËèÖÐÏÂÓιÇËèϸ°ûºÍÁܰÍϸ°ûµÄÁ÷ʽϸ°ûÊõ·ÖÎö¡£
 
ͼ4£ºEAEСÊó¹ÇËèÖÐÐÔÁ£Ï¸°ûºÍLy6Chighµ¥ºËϸ°ûµÄÔìѪ¹¦ÄÜÔöÇ¿
 
(A) ʾÒâͼչʾ¹ÇËè HSC¡¢ÏÂÓÎ×æÏ¸°û¡¢¹ÇËèϸ°ûºÍÁܰÍϸ°ûµÄÆ×ϵ׷×Ù¡£
 
(B) Á÷ʽϸ°ûͼÏÔʾ14dpiʱָ¶¨×étdTomato±í´ïµÄHSC¡£
 
(C) ÔÚ7¡¢14ºÍ28 dpiʱ¶Ô±í´ï tdTomatoµÄHSCºÍÏÂÓιÇËè/ÁܰÍ×æÏ¸°ûµÄ¶¨Á¿·ÖÎö¡£
 
(D) Á÷ʽϸ°ûÒÇͼÏÔʾ14 dpi ʱ¹ÇËèÖбí´ï tdTomato µÄÖÐÐÔÁ£Ï¸°ûºÍLy6Chighµ¥ºËϸ°û¡£
 
(E)ÔÚÖ¸¶¨Ê±¼äµã¼ì²â¹ÇËèÖбí´ï tdTomato µÄÖÐÐÔÁ£Ï¸°û¡¢Ly6Chighµ¥ºËϸ°û¡¢Ê÷ͻ״ϸ°û¡¢B ϸ°ûºÍ T ϸ°ûµÄÊýÄ¿¡£
 
(F-H)Æ¢ÔࣨF£©¡¢ÑªÒº£¨G£©¡¢ÄԺͼ¹Ëè×éÖ¯£¨H£©Öбí´ï tdTomato µÄÖÐÐÔÁ£Ï¸°ûºÍ Ly6Chighµ¥ºËϸ°ûµÄÊýÄ¿¡£
 
 
ͼ5: ËèÇÊ·´Ó¦ÐÔ T ϸ°ûÓÅÏȹ鳲ÓÚ¹ÇËè²¢ÓÕµ¼¹ÇËèÉú³É
 
(A) Á÷ʽϸ°ûÊõ¼ì²â14 dpiʱСÊóѪҺ¡¢Æ¢Ôà¡¢Áܰͽᡢ¹ÇËè¡¢´óÄԺͼ¹ËèÖÐ MOG 35 – 55ÌØÒìÐÔCD4 + Tϸ°ûµÄ°Ù·Ö±È¡£
 
(B) ÔÚÖ¸¶¨Ê±¼äµã EAE СÊó¹É¹Ç¹ÇËèÖÐMOG 35 – 55ÌØÒìÐÔCD4 + Tϸ°ûµÄ°Ù·Ö±È¡£
 
(C) ʵÑéÉè¼ÆÊ¾Òâͼ¡£
 
(D) Á÷ʽϸ°ûÊõÆÀ¹À¹é³²ÖÁ¹É¹Ç¹ÇËèµÄ×ªÒÆ (GFP+) CD4 + Tϸ°û¡£
 
(E) ´ÓUBC-GFP EAEСÊóµÄÆ¢×éÖ¯ÖзÖÀë³öCD4 + Tϸ°û£¬²¢ÔÚÌåÍâÇõÍCXCR4£¬È»ºó½« 2 × 10 6 CD4 + Tϸ°û¾²Âö×¢Éäµ½ÊÜÌå Rag2 -/-СÊóÖС£Í¨¹ýÁ÷ʽϸ°ûÊõÔÚÊÜÌå Rag2 -/-СÊóÖмì²âGFP+ CD4+ Tϸ°û¡£
 
(F) ½øÐÐÁ÷ʽϸ°ûÊõ·ÖÎöÒÆÖ²ºóµÚ 7 ÌìÊÜÌåСÊóµÄ¹ÇËèϸ°û¡£
 
(G) Á÷ʽϸ°ûÊõ¼ì²âÔÚÊÜÌå Rag2 -/-СÊóÖеÄ2D2 Tϸ°û¡£
 
(H) ÊÜÌåRag2 -/-СÊó¹É¹Ç¹ÇËèÖÐHSCµÄ¼ÆÊý¼°Æä Ki67 µÄ±í´ï¡£
 
(I) ÊÜÌåRag2 -/-СÊó¹É¹Ç¹ÇËèÖÐ GMP¡¢MDP¡¢ÖÐÐÔÁ£Ï¸°ûºÍLy6Chighµ¥ºËϸ°ûµÄ¼ÆÊý¡£
 
 
ͼ6: ËèÇÊ·´Ó¦ÐÔTϸ°ûʹ¹ÇËèHSCÆ«ÏòËèϸ°ûÆ×ÏµÉæ¼°CCL5-CCR5Öá
 
(A) ÈÈͼÏÔʾ´ÓÓ×ÖÉ2D2СÊó¹É¹Ç¹ÇËèÖзÖÑ¡µÄ2D2 CD4 + Tϸ°û±í´ïµÄÃâÒßÒò×Ó¡£
 
(B)Á÷ʽϸ°ûÊõ·ÖÎö 2D2СÊó»òÒ°ÉúÐÍСÊó¹ÇË衢ƢÔàºÍÁܰͽá2D2 CD4 + Tϸ°ûÖÐCCL5µÄ±í´ïÇé¿ö¡£
 
(C)´Ó 2D2 СÊóºÍÒ°ÉúÐÍСÊóµÄ¹É¹Ç¹ÇËèÖзÖÑ¡³öHSCµÄת¼×éͼÆ×£¬ÈÈͼ±íÃ÷±ä»¯»ùÒòµÄZÖµ¡£
 
(D) Á÷ʽϸ°ûÒÇͼºÍÌõÐÎͼ±íÃ÷ 2D2 »òÒ°ÉúÐÍСÊó×éµÄ¹ÇËè HSCÖÐCCR5µÄ±í´ïÁ¿Éϵ÷¡£
 
(E) µ¥Ï¸°û²âÐò·ÖÎö±íÃ÷£¬MS»¼Õß¹ÇËèÖбí´ïCCL5µÄTϸ°ûºÍ±í´ïCCR5µÄ HSCµÄÊýÄ¿Ôö¼Ó¡£
 
(F) ʵÑéÉè¼ÆÊ¾Òâͼ¡£
 
(G) Á÷ʽϸ°ûÊõ·ÖÎösi CCL5´¦ÀíºóCD4 +Tϸ°ûÖÐCCL5±í´ïÇé¿ö¡£
 
(H) CCL5ÇõͺóÊÜÌåСÊó¹ÇËèÖÐ2D2 CD4 +Tϸ°ûµÄ°Ù·Ö±È¡£
 
(I)Á÷ʽϸ°ûÊõ·ÖÎöCCL5ÇõͺóÊÜÌåСÊóÖÐHSC¡¢GMP¡¢MDP¡¢ÖÐÐÔÁ£Ï¸°ûºÍLy6Chighϸ°û¡£
 
ͼ7£ºCCL5-CCR5ÖáµÄÆÆ»µÒÖÖÆ¹ÇËèÉú³É¡¢Éñ¾­Ñ×Ö¢ºÍÉñ¾­¹¦ÄÜȱËð
 
(A) ʵÑéÉè¼ÆÊ¾Òâͼ¡£
 
(B)Á÷ʽϸ°ûÊõ·ÖÎö½ÓÊÜ2D2 CD4+Tϸ°û»òÓ×ÖÉÒ°ÉúÐÍCD4+Tϸ°ûºóСÊó¹ÇËèÖÐCD45.2+µÄHSCϸ°û¡£
 
(C) Á÷ʽϸ°ûÊõ·ÖÎö½ÓÊÜ2D2 CD4+ Tϸ°ûºóСÊóCD45.2+µÄÏÂÓιÇËè×æÏ¸°û¡£
 
(D&E) Á÷ʽϸ°ûÊõ·ÖÎö½ÓÊÜ2D2 CD4+ Tϸ°ûµÄСÊó¹ÇËè (D)¡¢ÄԺͼ¹Ëè (E)ÖÐ CD45.2+ÖÐÐÔÁ£Ï¸°ûºÍLy6Chighµ¥ºËϸ°û¡£
 
(F) ¶Ô·Ö±ð½ÓÊÜCCR5 +/+ Lin -ϸ°û»òCCR5 -/- Lin -ϸ°ûÈ»ºó×¢Éä2D2 CD4+Tϸ°ûµÄСÊó½øÐÐÁÙ´²ÆÀ·Ö¡£
 
(G) СÊó¼¹Ëè×éÖ¯ÇÐÆ¬H&EºÍLuxol Fast blueȾɫ¡£
 
 
×ܽá
 
¶à·¢ÐÔÓ²»¯Ö¢²¡ÒòѧµÄÖ÷ÒªÑо¿¼¯ÖÐÔÚÖÐÊàÉñ¾­ÏµÍ³µÄ×ÔÉí·´Ó¦ÐÔT ϸ°ûÉÏ£¬ÕâЩTϸ°ûÒ»µ©½øÈëÖÐÊàÉñ¾­ÏµÍ³¾Í»áÖØÐ¼¤»î²¢Òý·¢Ñ×ÐÔÍÑËèÇʲ¡±ä¡£¾¡¹ÜÔ½À´Ô½¶àµÄÖ¤¾Ý±íÃ÷ÖÐÐÔÁ£Ï¸°ûºÍµ¥ºËϸ°ûÔÚ¶à·¢ÐÔÓ²»¯Ö¢ÆÚ¼ä»á¼Ì·¢ÖÐÊàÉñ¾­ÏµÍ³Ñ×Ö¢£¬µ«ÕâЩѪԴÐÔϸ°ûµÄÆðÔ´ÈÔȻδ֪¡£
ÕâÏîÑо¿±¨µÀÁ˹ÇËè¿Éµ÷¿ØÖÐÊàÉñ¾­ÏµÍ³Ñ×Ö¢ºÍ×ÔÉíÃâÒßËðÉË´«²¥£¬¸³Óè¹ÇËèÒ»¸öδ±»ÈÏÖªµÄ¹¦ÄÜ¡£È»¶ø£¬Ñо¿Õß»¹Ã»Óеóö½áÂÛÐÔÖ¤¾Ý£¬Ö¤Ã÷ÖÐÊàÉñ¾­ÏµÍ³ÖÜΧ¹ÇËèÓë¹É¹Ç¹ÇËè¶ÔÖÐÊàÉñ¾­ÏµÍ³Ñ×Ö¢ËðÉ˵ÄÓ°Ïì¡£´ËÍ⣬¶à·¢ÐÔÓ²»¯Ö¢¹ÇËèÒì³£ÔöÉúºóTϸ°ûµÄÀ©ÔöºÍTCR VβÓ¦ÓõĻúÖÆ»¹ÐèÒª½øÒ»²½Ñо¿¡£
ÉÏһƪ£ºÊ¯Ñ§ÃôÖÎÁƸßѪѹ²¡¾­Ñé   ÏÂһƪ£ºNature×Ó¿¯¾¯¸æ£ºCRISPR±à¼­´æÔÚÒ»ÖÖÒÔǰδ±»·¢ÏÖµÄDZÔÚΣÏÕ
°æÈ¨ËùÓÐ:Ìì½òº£±õÈËÃñÒ½Ôº µØÖ·:Ìì½òÊдó¸ÛÓÍÌï ÍøÕ¾µØÍ¼        ½òICP±¸£º09008725    ÄúÊÇµÚ 153877λ·ÃÎÊÕß